Lab Genomics Revolutionizes Cancer Diagnosis with Next-Generation Sequencing (NGS) Tests

Lab Genomics has developed a comprehensive portfolio of NGS tests, including OTD Lung, a non-small cell lung cancer level 1 companion diagnostic service, OTD Liquid, a solid tumor pre-cancer level 2 analysis service, OTD Liquid, a solid tumor liquid biopsy service, and HemaScan, a blood cancer pre-cancer analysis service. This achievement is a result of the company’s commitment to ‘Open R&D’ and ‘Open Innovation’ as a sustainable growth strategy.

Notably, OTD Lung is being evaluated for its potential to change the paradigm of lung cancer treatment. This innovative test enables the identification of various genetic mutations with a small sample and rapid drug selection within 10 days.

An official from the Lab Genomics Hospital Solutions Team highlighted the advantages of OTD Lung, stating, “Unlike traditional fluorescence in situ hybridization (FISH) diagnosis or real-time polymerase chain reaction (real-time PCR) diagnosis, OTD Lung can diagnose positivity for various genetic mutations with a single test and even prescribe medication.” Additionally, “NGS panel-based screening reimbursement testing for non-small cell lung cancer (NSCLC) adenocarcinoma can be tested at up to 61% lower price, allowing for rapid sales growth as the patient’s share of the cost is lower compared to other types of cancer.”

Lab Genomics reported that the positive rate for drug use in the OTD Lung test conducted since the service launch last year through August of this year was 49% of all tests. This represents a positive rate 2-3 times higher than the existing real-time polymerase chain reaction method for each gene, providing treatment opportunities to more patients. The company aims to continuously expand cancer diagnosis and introduce it to the U.S. CleaLab to grow its appearance and profitability.

Kim Jung-joo, CEO of Lab Genomics, emphasized the company’s mission, stating, “All executives and employees are committed to providing fast and accurate analysis results so that at least one more cancer patient can have a chance at treatment.” He added, “We will leverage our expertise and references related to cancer diagnosis, accumulated over eight years, to introduce it to CliaLab in the U.S. and expand the ‘K-Cancer Diagnosis’ service.”